Eastern Capital Ltd Insider Trading for 1.30 million Shares of TapImmune, Inc. (TPIV); Cushing Asset Management LP Cut Its Qep Res (QEP) Stake

TapImmune, Inc. (NASDAQ:TPIV) Logo

Cushing Asset Management Lp decreased Qep Res Inc (QEP) stake by 24.64% reported in 2017Q4 SEC filing. Cushing Asset Management Lp sold 102,000 shares as Qep Res Inc (QEP)’s stock declined 2.19%. The Cushing Asset Management Lp holds 312,000 shares with $2.99M value, down from 414,000 last quarter. Qep Res Inc now has $3.09 billion valuation. The stock increased 0.23% or $0.03 during the last trading session, reaching $13.02. About 4.15M shares traded. QEP Resources, Inc. (NYSE:QEP) has declined 22.78% since May 17, 2017 and is downtrending. It has underperformed by 34.33% the S&P500.

Eastern Capital Ltd, an insider of Tapimmune Inc a few days ago purchased 1.30 million shares of the British Columbia – Canada-based company. The substantial insider purchase has $3.12 million U.S. Dollars total value, at an average price per share of $2.4. This trade was pretty huge one, so clearly it won’t go disregarded. At the moment, Eastern Capital Ltd has ownership of 5.30 million shares or roughly 49.88% of the company’s total market cap.

More notable recent TapImmune, Inc. (NASDAQ:TPIV) news were published by: Bizjournals.com which released: “Merger takes Jacksonville immunotherapy company to Houston” on May 15, 2018, also Prnewswire.com with their article: “TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform” published on May 16, 2018, Prnewswire.com published: “TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno ..” on May 15, 2018. More interesting news about TapImmune, Inc. (NASDAQ:TPIV) were released by: Prnewswire.com and their article: “TapImmune to Present at 2018 NYC Oncology Investor Conference” published on May 07, 2018 as well as Benzinga.com‘s news article titled: “32 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: May 01, 2018.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company has market cap of $34.64 million. It specializes in the development of immunotherapies targeting women's cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers. It currently has negative earnings. The company's peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

The stock increased 7.59% or $0.23 during the last trading session, reaching $3.26. About 153,209 shares traded or 247.91% up from the average. TapImmune, Inc. (NASDAQ:TPIV) has declined 26.26% since May 17, 2017 and is downtrending. It has underperformed by 37.81% the S&P500.

Analysts await QEP Resources, Inc. (NYSE:QEP) to report earnings on July, 25. They expect $-0.15 EPS, down 25.00% or $0.03 from last year’s $-0.12 per share. After $-0.20 actual EPS reported by QEP Resources, Inc. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

More recent QEP Resources, Inc. (NYSE:QEP) news were published by: Globenewswire.com which released: “New Research: Key Drivers of Growth for root9B Holdings Inc., Comfort Systems, SS&C Technologies, ZIOPHARM …” on May 16, 2018. Also Globenewswire.com published the news titled: “QEP Resources Reports First Quarter 2018 Financial and Operating Results” on April 25, 2018. Streetinsider.com‘s news article titled: “Elliott’s 13F Shows New Stake in Commault (CVLT), Dish (DISH), Micro Focus (MFGP) (more…)” with publication date: May 15, 2018 was also an interesting one.

Since March 8, 2018, it had 1 buying transaction, and 0 insider sales for $90,000 activity. On Thursday, March 8 TRICE DAVID A bought $90,000 worth of QEP Resources, Inc. (NYSE:QEP) or 10,000 shares.

Among 27 analysts covering QEP Resources (NYSE:QEP), 13 have Buy rating, 1 Sell and 13 Hold. Therefore 48% are positive. QEP Resources has $29 highest and $8 lowest target. $14.74’s average target is 13.21% above currents $13.02 stock price. QEP Resources had 71 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets on Thursday, January 11 with “Buy”. FBR Capital maintained the shares of QEP in report on Friday, March 9 with “Hold” rating. As per Tuesday, July 18, the company rating was downgraded by Deutsche Bank. The stock has “Overweight” rating by Barclays Capital on Tuesday, September 26. As per Thursday, November 19, the company rating was upgraded by Goldman Sachs. As per Wednesday, March 14, the company rating was maintained by Piper Jaffray. The stock has “Outperform” rating by BMO Capital Markets on Monday, July 18. As per Tuesday, November 21, the company rating was upgraded by Mizuho. Stifel Nicolaus maintained the shares of QEP in report on Monday, April 23 with “Buy” rating. Credit Suisse initiated the shares of QEP in report on Monday, December 11 with “Sell” rating.

Cushing Asset Management Lp increased Firstenergy Corp (NYSE:FE) stake by 20,000 shares to 110,000 valued at $3.37 million in 2017Q4. It also upped Andeavor Logistics Lp stake by 7,739 shares and now owns 2.14 million shares. Spectra Energy Partners Lp (NYSE:SEP) was raised too.

QEP Resources, Inc. (NYSE:QEP) Institutional Positions Chart